Osimertinib, platinum, and etoposide for patients with metastatic EGFR / TP53 / RB1 -mutant lung cancers at risk for histological transformation
Lena Morrill Gavarró, Monica F. Chen, Àlvaro Quintanal-Villalonga, Yufei Deng, Liancheng Lu, Britney Forsyth, Sahil Sahni, Eric G. Sun, Swanand Rakhade, Rania Gaber Mohamed Aly, Meng Wang, Amin H. Sabet, P Solanki, Christina E. Wilson, Natasha Rekhtman, Sam E. Tischfield, Jake June-Koo Lee, Khadeja A. Moses, Linda Su Hyun Ahn, Clare Wilhelm, Amanda Pupo, Christina J. Falcon, Andrea Arfè, Katherine S. Panageas, Mark G. Kris, Parvathy Manoj, Ignas Masilionis, Ojasvi Chaudhary, Ronan Chaligné, Esther Redín, Eric E. Gardner, Xinjun Wang, Dana Pe’er, Charles M. Rudin, Joseph Minhow Chan, Helena Alexandra Yu
Peer-reviewed journalReal-world use
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
Despite the addition of SCLC-directed chemotherapy, nearly half of patients (5 of 11) underwent SCLC transformation, with median progression-free survival of 11 months and overall survival of 33 months.
These findings map chemotherapy-induced CAF plasticity, reveal a TMEM100-AREG axis of resistance, and highlight TMEM100 + CAFs as a promising target to sensitize PDAC to neoadjuvant treatment.
Haorui Li, Xi Ma, Xupeng Hou and 15 more — Science Translational Medicine
Progression-free survival was longer in Dato-DXd-treated (median 7.2 versus 4.0 months; hazard ratio 0.40, 95% confidence interval 0.25–0.64) but not docetaxel-treated (median 4.1 versus 4.4 months; hazard ratio 0.94, 95% confidence interval 0.59–1.49) patients with TROP2 NMR-positive versus TROP2 NMR-negative samples (treatment by biomarker status interaction P = 0.0098), indicating that TROP2 NMR may be a predictive biomarker for Dato-DXd.
Marina Chiara Garassino, Myung‐Ju Ahn, Markus Schick and 22 more — Nature Medicine
They highlight epithelial and mucus barrier-related pathways in seropositive AG/SAG and immune-related pathways in seronegative cases, while also providing evidence of a shared genetic basis between AG and GC.
T. Kyosaka, A. Narita, A. Miyake and 45 more — medRxiv